Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

Status:

Active, not recruiting

Phase 3 Icon

Trial Phase

The investigational immunotherapy is being studied in a large group of patients to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the investigational immunotherapy to be used safely.

Eligibility

About the Trial

All patients who enroll in the trial will receive medication while on the study.

  • 50% will receive pembrolizumab along with ipilimumab*
  • 50% will receive pembrolizumab along with placebo

*Neither you nor the study doctor will know what you are receiving. In case of a health emergency, the study doctor can get this information.  

Trial Purpose
25

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03302234 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Carcinoma, Non-Small-Cell Lung

Age range

18 — no age maximum

Gender(s)

All

Trial Purpose

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

    Location
    Status
  • Phoenix, Arizona, United States, 85054
    Not Recruiting
  • Burbank, California, United States, 91505
    Not Recruiting
  • Monterey, California, United States, 93940
    Not Recruiting
  • Santa Monica, California, United States, 90404
    Not Recruiting
  • Orlando, Florida, United States, 32804
    Not Recruiting
  • Scarborough, Maine, United States, 04074
    Not Recruiting
  • Boston, Massachusetts, United States, 02118
    Not Recruiting
  • Burlington, Massachusetts, United States, 01805
    Not Recruiting
  • Teaneck, New Jersey, United States, 07666
    Not Recruiting
  • New York, New York, United States, 10029
    Not Recruiting
  • Columbus, Ohio, United States, 43210
    Not Recruiting
  • Columbus, Ohio, United States, 43219
    Not Recruiting
  • Portland, Oregon, United States, 97213
    Not Recruiting
  • Greenville, South Carolina, United States, 29615
    Not Recruiting
  • Chattanooga, Tennessee, United States, 37403
    Not Recruiting
  • Knoxville, Tennessee, United States, 37909
    Not Recruiting
  • Arlington, Texas, United States, 76014
    Not Recruiting
  • Dallas, Texas, United States, 75203
    Not Recruiting
  • Flower Mound, Texas, United States, 75028
    Not Recruiting
  • Longview, Texas, United States, 75601
    Not Recruiting
  • Vancouver, Washington, United States, 98684
    Not Recruiting
  • Yakima, Washington, United States, 98902
    Not Recruiting
  • Madison, Wisconsin, United States, 53792
    Not Recruiting
  • Milwaukee, Wisconsin, United States, 53226
    Not Recruiting
  • Paducah, Kentucky, United States, 42003
    Not Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Keynote number

A unique identification code used by the sponsor to identify a specific trial.
Keynote-598

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.